Skip to main content
APTOF
OTC Life Sciences

Glass Lewis Recommends Shareholders Vote 'FOR' Hanmi Pharmaceutical Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.611
Mkt Cap
$4.112M
52W Low
$0.636
52W High
$229.5
52W Position info
153% above low
Off High info
99% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

APTOF has more than doubled off its 52-week low of $0.636.

Summary

Aptose Biosciences announced that Glass Lewis, a leading proxy advisory firm, recommends shareholders vote 'FOR' the acquisition by Hanmi Pharmaceutical, reinforcing the likelihood of the deal's approval.


Key Events · M&A and Partnerships · APTOF

  • Glass Lewis Endorses Acquisition

    Glass, Lewis & Co., a leading independent proxy advisory firm, has recommended that Aptose shareholders vote 'FOR' the special resolution to approve the previously announced arrangement with Hanmi Pharmaceutical Co. Ltd.

  • Shareholder Meeting and Voting Deadline Reminder

    Shareholders are reminded to submit their proxies by 11:00 a.m. (EST) on Friday, March 27, 2026, for the special meeting reconvened to March 31, 2026, to vote on the Arrangement and a Continuance.

  • Board Recommendation Reaffirmed

    Aptose's Special Transaction Committee and Board of Directors unanimously recommend that shareholders vote 'FOR' the special resolutions approving the Continuance and the Arrangement.


Analysis · APTOF · Life Sciences

This filing announces that Glass Lewis, a prominent independent proxy advisory firm, has recommended that Aptose Biosciences shareholders approve the proposed acquisition by Hanmi Pharmaceutical. This follows a similar recommendation from ISS, as disclosed in a recent filing. The endorsement from another major proxy advisor significantly strengthens the likelihood of shareholder approval for the acquisition and the associated continuance, moving the company closer to completing this major corporate transaction. Shareholders are reminded to vote by the March 27, 2026 deadline for the reconvened special meeting on March 31, 2026.

At the time of this filing, APTOF was trading at $1.61 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.64 to $229.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APTOF - Latest Insights

APTOF
Jun 30, 2026, 7:32 PM EDT
Source: GlobeNewswire
Importance Score:
10
Price at Filing: $1.62
Real-time Price: $1.69 info
Change: +$0.070 (+4%) info
Market Cap: $4.314M info
APTOF
Jun 15, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.61
Real-time Price: $1.69 info
Change: +$0.0775 (+5%) info
Market Cap: $4.314M info
APTOF
May 29, 2026, 8:04 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.57
Real-time Price: $1.69 info
Change: +$0.120 (+8%) info
Market Cap: $4.314M info
APTOF
May 13, 2026, 5:21 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.70
Real-time Price: $1.69 info
Change: -$0.010 (-0.59%) info
Market Cap: $4.314M info
APTOF
May 13, 2026, 5:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1.70
Real-time Price: $1.69 info
Change: -$0.010 (-0.59%) info
Market Cap: $4.314M info